Comparative Pharmacology
Head-to-head clinical analysis: DESMODA versus DIAPID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESMODA versus DIAPID.
DESMODA vs DIAPID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.
10 mg orally once daily
Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.
None Documented
None Documented
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Terminal elimination half-life is 1.5-3 hours; clinically significant in patients with renal impairment, requiring dose adjustment
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Primarily renal excretion as unchanged drug (80-90%); minor biliary/fecal elimination (<10%)
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog